ACTINIUM PHARMACEUTICALS, INC. Cost of Revenue
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Cost of Revenue of $900.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-25.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2022-03-25
- ACTINIUM PHARMACEUTICALS, INC. cost of revenue for fiscal 2021 was $900.00K.
| Period end | Cost of Revenue 12 month |
|---|---|
| 2021-12-31 | $900.00K 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |